Frontline Tislelizumab Improves Survival in PD-L1+, Advanced Gastric/GEJ cancer
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.
Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.
The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.
Adding bemarituzumab to chemotherapy improved overall survival in FGFR2b-expressing gastric or gastroesophageal junction cancer.
Patients with diverticular disease had an increased risk of lung, prostate, breast, hematologic, colorectal, gastric, liver, and pancreatic cancers.
The risk of ILD/pneumonitis was associated with patient age, time since cancer diagnosis, dose of trastuzumab deruxtecan, and other factors.
At 5 years, OS and RFS rates were similar with laparoscopic surgery and open distal gastrectomy.
Counties in the Southeastern United States primarily accounted for the highest 5% of mortality rates for gastric, pancreatic, and colorectal cancer.
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.